Deanxit

Flupentixol 0.5 mg, melitracen 10 mg

Anxiety-depression.

Adult Usually 2 tab daily in the morning & noon. May increase morning dose to 2 tab in severe cases. Max: 4 tab daily. Elderly >65 yr 1 tab in the morning. 2 tab daily in the morning & at noon in severe cases. Maintenance dose: 1 tab in the morning.

May be taken with or without food.

Hypersensitivity. Circulatory collapse, depressed level of consciousness due to any cause, coma, blood disorders, phaeochromocytoma, recent MI, any degree of AV block or cardiac rhythm disorders & coronary artery insufficiency. Concomitant treatment w/ MAOIs.

Not to be used w/ MAOIs & drugs that may cause QT prolongation. Patients w/ organic brain syndrome, convulsion, urinary retention, hyperthyroidism & advanced hepatic or CV disease. Not recommended for excitable or overactive patients. Gradually w/draw in patients treated w/ tranquilizers or neuroleptics w/ sedative effect. Possibility of development of neuroleptic malignant syndrome. Patients w/ hypokalaemia, hypomagnesemia, genetic predisposition; w/ history of CV disorders (eg, QT prolongation, significant bradycardia, recent acute MI, uncompensated heart failure or cardiac arrhythmia). Closely monitor patients w/ depression & suicidal thoughts. May modify insulin & glucose response in diabetic patients. Patients w/ rare condition of shallow anterior chamber & narrow chamber angle & attacks of acute glaucoma may be provoked. Risk of arrhythmias & hypotension w/ anaesth; discontinue treatment if emergency surgery is unavoidable. Patients receiving SSRIs. Identify risk factors for VTE prior to & during therapy. Not for dementia-related behavioural disturbances. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Pregnancy & lactation. Childn & adolescent <18 yr. Elderly w/ risk factors for stroke.

Insomnia, agitation, restlessness; somnolence, tremor, dizziness; dry mouth, constipation; fatigue; prolonged ECG QT.

Risk of serotonin syndrome w/ non-selective as well as selective A (moclobemide) & B (selegiline) MAOIs. May potentiate CV effects of adrenaline, ephedrine, isoprenaline, noradrenaline, phenylephrine & phenylpropanolamine (eg, as contained in local & general anaesth & nasal decongestants). May counteract antihypertensive effects of guanethidine, betanidine, reserpine, clonidine & methyldopa. Increased risk of paralytic ileus, hyperpyrexia w/ anticholinergic agents. May increase QT interval w/ class Ia & III antiarrhythmics (eg, quinidine, amiodarone, sotalol, dofetilide), antipsychotics (eg, thioridazine), macrolides (eg, erythromycin), antihistamine (eg, terfenadine, astemizole), quinolone antibiotics (eg, gatifloxacin, moxifloxacin), cisapride, lithium. Increase QT prolongation & malignant arrhythmias w/ thiazide diuretics. May enhance effects of alcohol, barbiturates & other CNS depressants. Increased neurotoxicity w/ lithium. May reduce the effect of levodopa & increase risk of cardiac side effects.

Antidepressants / Anxiolytics

N06CA02 - melitracen and psycholeptics ; Belongs to the class of antidepressants in combination with psycholeptics.

D